HER2CLIMB: Targeting Stable and Active Brain Metastases in Advanced HER2+ Breast Cancer

The assistance of AI-based computer-aided detection for mammogram screenings did not impact recall rates in a radiologist’s standard single reading.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Axillary management of patients with breast cancer such as sentinel lymph node biopsy have evolved substantially over the past 30 years.

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

Pathologic complete response rates with the atezolizumab combination were higher for patients with PD-L1–negative disease in the phase 2 ATHENE trial.

After treatment with an aromatase inhibitor plus a CDK4/6 inhibitor, switching to camizestrant plus a CDK4/6 inhibitor showed a PFS benefit over remaining on the aromatase inhibitor.